CH EPL (R5)
1.0.0 - trial-use
CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions
Profile: IDMP RegulatedAuthorization
CH - EPL Reimbursement SL
url
FOPHDossierNumbervalue: FOPH Dossier Number/21208
url
statusvalue: Reimbursed
url
statusDatevalue: 2021-08-01
url
listingStatusvalue: Listed
url
listingPeriodvalue: 2021-08-01 --> (ongoing)
url
firstListingDatevalue: 2021-08-01
url
costSharevalue: 10
url
gammevalue: Oral
value: CHF3,022.10 (CHF)
type: Ex-factory price
changeType: Price mutation after triennal review of pharmaceuticals
changeDate: 2024-01-01
url
CH - EPL Product Pricevalue: CHF3,347.10 (CHF)
type: Retail price
changeType: VAT-change
changeDate: 2024-01-01
url
CH - EPL Product Price
type: Reimbursement SL
| Extension | Reference |
| ClinicalUseDefinition: type = indication |
holder: Organization Curatis AG
Generated Narrative: Organization #holder-Curatis-AG
Profile: CH EPL Organization
identifier: LOC Identifier/100082791, GLN Identifier/7640109110007
name: Curatis AG